Shots: Veila Bio to receive $30M upfront licensing fee, additional payment on development and commercial milestones plus royalties on sales of product post-launch MTPC to get exclusive rights to develop […]readmore
Tags : Mitsubishi Tanabe
Shots: The P-III BouNDLess study involves assessing of continuous carbidopa/levodopa (ND0612, SC) infusion vs immediate-release carbidopa/levodopa (CD/LD, PO) in 300 patients with PD experiencing motor fluctuations, evaluating its safety, efficacy […]readmore
Regulatory
Mitsubishi Tanabe’s Edaravone Receives NMPA’s Approval for Amyotrophic Lateral Sclerosis
Shots: Post MHLW approval in Japan in 2015, the company has received NMPA approval for Edaravone and is approved in six countries of China. Additionally, the product is approved in […]readmore